Cqt.Ax

CQT.AX has a highly leveraged capital structure, with a debt-to-equity ratio of 5.79, indicating a significant reliance on debt financing. The company's liquidity position is rated as medium, with a current ratio of 0.9, suggesting limited short-term liquidity to cover immediate obligations. The negative net cash position after subtracting total debt further highlights the company's liquidity constraints.

Profitability metrics for CQT.AX are severely negative, with a return on equity of -28.72% and a return on assets of -1.95%, both well below the industry median for the Advanced Medical Equipment & Technology sector. The company reported a net loss of $18.19 million and an operating loss of $12.79 million, indicating a lack of operational profitability.

CQT.AX does not disclose segment or geographic revenue breakdowns in the available data, making it difficult to assess revenue concentration or geographic exposure. The absence of segment data limits the ability to evaluate the company's diversification and risk profile across different product lines or regions.

The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The negative operating and free cash flows suggest a lack of financial flexibility to fund growth initiatives or meet ongoing obligations.

CQT.AX faces significant financial risks, including a high debt-to-equity ratio and negative cash flows, which could lead to liquidity constraints and potential refinancing challenges. The company's dilution potential is rated as low, with no evidence of recent share issuance or dilutive events in the available data.

Recent events for CQT.AX are not detailed in the available data, and there are no disclosed filings or transcripts that provide insight into the company's strategic direction or operational performance.